Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease.
Marit JalinkChaja F JacobsJahanzaib KhwajaDorothea EversCoty BruggemanBruno FattizzoMarc MichelEtienne CrickxQuentin A A HillUlrich JägerArnon P KaterAnja B U MäkelburgAnouk BreedijkPeter A W Te BoekhorstMarlijn P A HoeksMasja de HaasShirley D'SaJosephine M I M I VosPublished in: Blood advances (2024)
Autoimmune hemolytic anemia (AIHA) is a rare autoantibody-mediated disease. For steroid and/or rituximab-refractory AIHA, there is no consensus on optimal treatment. Daratumumab, a monoclonal antibody targeting CD38, could be beneficial by suppression of CD38+ plasma cells and thus autoantibody secretion. In addition, because CD38 is also expressed by activated T cells, daratumumab may also act via immunomodulatory effects. We evaluated the efficacy and safety of daratumumab monotherapy in an international retrospective study including 19 adult patients with heavily pretreated refractory AIHA. In warm AIHA (wAIHA, n = 12), overall response was 50% with a median response duration of 5.5 months (range, 2-12), including ongoing response in 2 patients after 6 and 12 months. Of 6 nonresponders, 4 had Evans syndrome. In cold AIHA (cAIHA, n = 7) overall hemoglobin (Hb) response was 57%, with ongoing response in 3 of 7 patients. One additional patient with nonanemic cAIHA was treated for severe acrocyanosis and reached a clinical acrocyanosis response as well as a Hb increase. Of 6 patients with cAIHA with acrocyanosis, 4 had improved symptoms after daratumumab treatment. In 2 patients with wAIHA treated with daratumumab, in whom we prospectively collected blood samples, we found complete CD38+ T-cell depletion after daratumumab, as well as altered T-cell subset differentiation and a severely diminished capacity for cell activation and proliferation. Reappearance of CD38+ T cells coincided with disease relapse in 1 patient. In conclusion, our data show that daratumumab therapy may be a treatment option for refractory AIHA. The observed immunomodulatory effects that may contribute to the clinical response deserve further exploration.
Keyphrases
- multiple myeloma
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- combination therapy
- multiple sclerosis
- cell death
- signaling pathway
- stem cells
- prognostic factors
- peritoneal dialysis
- mesenchymal stem cells
- induced apoptosis
- machine learning
- diffuse large b cell lymphoma
- drug induced
- patient reported outcomes
- early onset
- electronic health record
- free survival
- sleep quality
- red blood cell